1. Doxazosin and hydrochlorothiazide equally affect arterial wall thickness in hypertensive males with hypercholesterolaemia (the DAPHNE study). Doxazosin Atherosclerosis Progression Study in Hypertensives in the Netherlands;Hoogerbrugge;Netherlands Journal of Medicine,2002
2. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease;Ostergren;European Heart Journal,2004
3. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large simple randomised trial of an angiotensin converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events;Canadian Journal of Cardiology,1996
4. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators;Yusuf;New England Journal of Medicine,2000
5. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators;Yusuf;New England Journal of Medicine,2000